Journal article icon

Journal article

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: the DECODE-CKD Trial

Abstract:

Background SGLT2 inhibitors, originally developed as glucose-lowering agents for treatment of type 2 diabetes, have been shown to have cardio- and kidney-protective effects among CKD patients with and without diabetes. However, the mechanisms remain largely unknown.

Methods Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD) is an investigator-initiated, prospective, sin...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.34067/KID.0006982022

Authors


Publisher:
American Society of Nephrology
Journal:
Kidney360 More from this journal
Volume:
4
Issue:
2
Pages:
143–149
Publication date:
2022-12-18
Acceptance date:
2022-11-30
DOI:
EISSN:
2641-7650
Language:
English
Keywords:
Pubs id:
1325875
Local pid:
pubs:1325875
Deposit date:
2023-02-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP